<?xml version="1.0" encoding="utf-8"?>
<feed xmlns="http://www.w3.org/2005/Atom" xmlns:bx="http://bx.businessweek.com">
<title>Competitive Intelligence - Business Exchange</title>
<subtitle>Most Active Articles</subtitle>
<link href="http://bx.businessweek.com/competitive-intelligence/most-active/feed" rel="self"/>
<link href="http://bx.businessweek.com/competitive-intelligence"/>
<updated>2009-11-24T00:52:58.404-05:00</updated>
<author>
<name>Business Exchange</name>
<email>Business_Exchange@businessweek.com</email>
</author>
<id>urn:com:businessweek:bx:topic:most-active:competitive-intelligence</id>
<bx:suggester>
<bx:fullname>John McGonagle</bx:fullname>
<bx:id>jmcgonagle370</bx:id>
<bx:link href="http://bx.businessweek.com/profile/john-mcgonagle/jmcgonagle370/"/>
</bx:suggester>
<entry>
<title>Competitors - Rotten SOB&#39;s or Valuable Strategic Alliance? (selling your business to a competitor)</title>
<link href="/competitive-intelligence/competitors---rotten-sobs-or-valuable-strategic-alliance-selling-your-business-to-a-competitor/8937263251557443551-2a4bd67570ef0834efec38c57f37c895/"/>
<id>urn:com:businessweek:bx:article:8937263251557443551-2a4bd67570ef0834efec38c57f37c895</id>
<updated>2009-11-23T22:00:29.239-05:00</updated>
<summary>Competitors – Friend or Foe ? Competitors can simply be defined as “one selling or buying goods or services in the same market as another” … per Merriam Dictionary or “those rotten http://bx.businessweek.com/competitive-intelligence/#add-article?articleType=NEWSSOB’s that undercut my pricing, run their...</summary>
<content type="html">Competitors – Friend or Foe ? Competitors can simply be defined as “one selling or buying goods or services in the same market as another” … per Merriam Dictionary or “those rotten http://bx.businessweek.com/competitive-intelligence/#add-article?articleType=NEWSSOB’s that undercut my pricing, run their...</content>
<source>
<title>noobpreneur.com</title>
</source>
<bx:external-link>http://www.noobpreneur.com/2009/11/23/competitors-rotten-sobs-or-valuable-strategic-alliance/</bx:external-link>
<bx:adder>
<bx:fullname>Ivan Widjaya</bx:fullname>
<bx:id>iwidjaya482</bx:id>
<bx:link href="http://bx.businessweek.com/profile/ivan-widjaya/iwidjaya482/"/>
</bx:adder>
<bx:action>
<bx:total>0</bx:total>
<bx:view>0</bx:view>
<bx:save>0</bx:save>
<bx:reaction>0</bx:reaction>
</bx:action>
</entry>
<entry>
<title>The blogopharmasphere?</title>
<link href="/competitive-intelligence/the-blogopharmasphere/5487041416984347101-c930006e50417497a7af477c0647f86f/"/>
<id>urn:com:businessweek:bx:article:5487041416984347101-c930006e50417497a7af477c0647f86f</id>
<updated>2009-11-11T02:36:19.817-05:00</updated>
<summary>http://www.the-scientist.com/blog/display/56142/</summary>
<content type="html">http://www.the-scientist.com/blog/display/56142/</content>
<source>
<title>the-scientist.com</title>
</source>
<bx:external-link>http://www.the-scientist.com/blog/display/56142/</bx:external-link>
<bx:adder>
<bx:fullname>Rashmi Pant</bx:fullname>
<bx:id>rpant537</bx:id>
<bx:link href="http://bx.businessweek.com/profile/rashmi-pant/rpant537/"/>
</bx:adder>
<bx:action>
<bx:total>2</bx:total>
<bx:view>1</bx:view>
<bx:save>0</bx:save>
<bx:reaction>1</bx:reaction>
</bx:action>
</entry>
<entry>
<title>CRO SNAPSHOT April- September 2009 - Clinical trials Phase 1 trials, Research blog of Veeda Group</title>
<link href="/competitive-intelligence/cro-snapshot-april--september-2009---clinical-trials-phase-1-trials-research-blog-of-veeda-group/17890505985866596108-97bb7823e0c97cfa2b663f1fc33ffe0b/"/>
<id>urn:com:businessweek:bx:article:17890505985866596108-97bb7823e0c97cfa2b663f1fc33ffe0b</id>
<updated>2009-11-10T07:07:46.466-05:00</updated>
<summary>The month of June 2009 witnessed activities which were responsible for 23% of the total happenings in the time frame of interest i.e. April-September 2009. Of the total activities, the highlight activities of the month were related to expansion of...</summary>
<content type="html">The month of June 2009 witnessed activities which were responsible for 23% of the total happenings in the time frame of interest i.e. April-September 2009. Of the total activities, the highlight activities of the month were related to expansion of...</content>
<source>
<title>blogs.veedacr.com</title>
</source>
<bx:external-link>http://blogs.veedacr.com/Lists/Posts/Post.aspx?ID=90</bx:external-link>
<bx:adder>
<bx:fullname>Rashmi Pant</bx:fullname>
<bx:id>rpant537</bx:id>
<bx:link href="http://bx.businessweek.com/profile/rashmi-pant/rpant537/"/>
</bx:adder>
<bx:action>
<bx:total>2</bx:total>
<bx:view>2</bx:view>
<bx:save>0</bx:save>
<bx:reaction>0</bx:reaction>
</bx:action>
</entry>
<entry>
<title>Indian Pharma - Clinical trials Phase 1 trials, Research blog of Veeda Group</title>
<link href="/competitive-intelligence/indian-pharma---clinical-trials-phase-1-trials-research-blog-of-veeda-group/17923857497913327171-e78582292c1c1d1dc711d47a9216e3a6/"/>
<id>urn:com:businessweek:bx:article:17923857497913327171-e78582292c1c1d1dc711d47a9216e3a6</id>
<updated>2009-11-10T07:21:11.881-05:00</updated>
<summary>An explicit indicator of the government intervention in the Corporate strategies of Indian companies is a headliner in todays&#39; key newspapers and also featuring in the news is an opinion from the Glenmark CEO. The published news has featured...</summary>
<content type="html">An explicit indicator of the government intervention in the Corporate strategies of Indian companies is a headliner in todays&#39; key newspapers and also featuring in the news is an opinion from the Glenmark CEO. The published news has featured...</content>
<source>
<title>blogs.veedacr.com</title>
</source>
<bx:external-link>http://blogs.veedacr.com/Lists/Categories/Category.aspx?Name=Indian%20Pharma</bx:external-link>
<bx:adder>
<bx:fullname>Rashmi Pant</bx:fullname>
<bx:id>rpant537</bx:id>
<bx:link href="http://bx.businessweek.com/profile/rashmi-pant/rpant537/"/>
</bx:adder>
<bx:action>
<bx:total>0</bx:total>
<bx:view>0</bx:view>
<bx:save>0</bx:save>
<bx:reaction>0</bx:reaction>
</bx:action>
</entry>
<entry>
<title>Bio-equivalence Studies - Clinical trials Phase 1 trials, Research blog of Veeda Group</title>
<link href="/competitive-intelligence/bio-equivalence-studies---clinical-trials-phase-1-trials-research-blog-of-veeda-group/11813651768703128027-6184ad3b801b4983b234d49e44b961bd/"/>
<id>urn:com:businessweek:bx:article:11813651768703128027-6184ad3b801b4983b234d49e44b961bd</id>
<updated>2009-11-10T07:08:48.315-05:00</updated>
<summary>The Top Listed CRO companies are facing tremendous pressure on their margins. Many are unable to maintain the same and are running into losses into millions of dollars each quarter. Quarterly results published every quarter and webcasts on the...</summary>
<content type="html">The Top Listed CRO companies are facing tremendous pressure on their margins. Many are unable to maintain the same and are running into losses into millions of dollars each quarter. Quarterly results published every quarter and webcasts on the...</content>
<source>
<title>blogs.veedacr.com</title>
</source>
<bx:external-link>http://blogs.veedacr.com/Lists/Categories/Category.aspx?Name=Bio%2dequivalence%20Studies</bx:external-link>
<bx:adder>
<bx:fullname>Rashmi Pant</bx:fullname>
<bx:id>rpant537</bx:id>
<bx:link href="http://bx.businessweek.com/profile/rashmi-pant/rpant537/"/>
</bx:adder>
<bx:action>
<bx:total>0</bx:total>
<bx:view>0</bx:view>
<bx:save>0</bx:save>
<bx:reaction>0</bx:reaction>
</bx:action>
</entry>
<entry>
<title>Cancer - Clinical trials Phase 1 trials, Research blog of Veeda Group</title>
<link href="/competitive-intelligence/cancer---clinical-trials-phase-1-trials-research-blog-of-veeda-group/6164801333215536596-1a345c6f0ea428e2cca4fbb80b51afd8/"/>
<id>urn:com:businessweek:bx:article:6164801333215536596-1a345c6f0ea428e2cca4fbb80b51afd8</id>
<updated>2009-11-10T07:15:33.091-05:00</updated>
<summary>A &quot;2&quot; way approach to business The Cancer Health forecasts are very promising and are expected to grow at a rate which is higher than the world pharma market growth rate. The market is expected to reach a an approximate size of greater than US $ 75...</summary>
<content type="html">A &quot;2&quot; way approach to business The Cancer Health forecasts are very promising and are expected to grow at a rate which is higher than the world pharma market growth rate. The market is expected to reach a an approximate size of greater than US $ 75...</content>
<source>
<title>blogs.veedacr.com</title>
</source>
<bx:external-link>http://blogs.veedacr.com/Lists/Categories/Category.aspx?Name=Cancer</bx:external-link>
<bx:adder>
<bx:fullname>Rashmi Pant</bx:fullname>
<bx:id>rpant537</bx:id>
<bx:link href="http://bx.businessweek.com/profile/rashmi-pant/rpant537/"/>
</bx:adder>
<bx:action>
<bx:total>0</bx:total>
<bx:view>0</bx:view>
<bx:save>0</bx:save>
<bx:reaction>0</bx:reaction>
</bx:action>
</entry>
<entry>
<title>New Drug Development (NCE) - Clinical trials Phase 1 trials, Research blog of Veeda Group</title>
<link href="/competitive-intelligence/new-drug-development-nce---clinical-trials-phase-1-trials-research-blog-of-veeda-group/3146372830617165237-e776fc7430d37dea205cd6a2fe3dac9e/"/>
<id>urn:com:businessweek:bx:article:3146372830617165237-e776fc7430d37dea205cd6a2fe3dac9e</id>
<updated>2009-11-10T07:12:11.646-05:00</updated>
<summary>Placebos are getting more &quot;effective&quot;. It sounds absurd but many &quot;clinical studies &quot;in the world of clinical research have proved so. This explains the success and failure of new drugs in the clinical trials during the process of drug development.</summary>
<content type="html">Placebos are getting more &quot;effective&quot;. It sounds absurd but many &quot;clinical studies &quot;in the world of clinical research have proved so. This explains the success and failure of new drugs in the clinical trials during the process of drug development.</content>
<source>
<title>blogs.veedacr.com</title>
</source>
<bx:external-link>http://blogs.veedacr.com/Lists/Categories/Category.aspx?Name=New%20Drug%20Development%20%28NCE%29</bx:external-link>
<bx:adder>
<bx:fullname>Rashmi Pant</bx:fullname>
<bx:id>rpant537</bx:id>
<bx:link href="http://bx.businessweek.com/profile/rashmi-pant/rpant537/"/>
</bx:adder>
<bx:action>
<bx:total>0</bx:total>
<bx:view>0</bx:view>
<bx:save>0</bx:save>
<bx:reaction>0</bx:reaction>
</bx:action>
</entry>
<entry>
<title>Pfizer Broke the Law by Promoting Drugs for Unapproved Uses</title>
<link href="/competitive-intelligence/pfizer-broke-the-law-by-promoting-drugs-for-unapproved-uses/1859469950159436038-39ac90417f5ca23ee0fb9718e8e1eb6b/"/>
<id>urn:com:businessweek:bx:article:1859469950159436038-39ac90417f5ca23ee0fb9718e8e1eb6b</id>
<updated>2009-11-09T02:09:14.864-05:00</updated>
<summary>Nov. 9 (Bloomberg) -- ProsecutorMichael Loucks remembers clearly when lawyers for Pfizer Inc., the world’s largest drug company, looked across the table and promised it wouldn’t break the law again. It was January 2004, and the attorneys were...</summary>
<content type="html">Nov. 9 (Bloomberg) -- ProsecutorMichael Loucks remembers clearly when lawyers for Pfizer Inc., the world’s largest drug company, looked across the table and promised it wouldn’t break the law again. It was January 2004, and the attorneys were...</content>
<source>
<title>bloomberg.com</title>
</source>
<bx:external-link>http://www.bloomberg.com/apps/news?pid=20601109&amp;sid=a4yV1nYxCGoA&amp;pos=10</bx:external-link>
<bx:adder>
<bx:fullname>Rashmi Pant</bx:fullname>
<bx:id>rpant537</bx:id>
<bx:link href="http://bx.businessweek.com/profile/rashmi-pant/rpant537/"/>
</bx:adder>
<bx:action>
<bx:total>0</bx:total>
<bx:view>0</bx:view>
<bx:save>0</bx:save>
<bx:reaction>0</bx:reaction>
</bx:action>
</entry>
<entry>
<title>Breast Cancer Vaccine Tests German Merck’s $1 Billion Strategy</title>
<link href="/competitive-intelligence/breast-cancer-vaccine-tests-german-mercks-1-billion-strategy/9906666587082922265-00eaeb34eb167e31a0f61972b70514d0/"/>
<id>urn:com:businessweek:bx:article:9906666587082922265-00eaeb34eb167e31a0f61972b70514d0</id>
<updated>2009-11-04T01:50:08.505-05:00</updated>
<summary>Nov. 4 (Bloomberg) -- Merck KGaA of Germany is gambling an unproven therapy that spurs the immune system to attack cancer cells will increase its share of a $48 billion oncology market. Merck is enrolling more than 900 women globally in an...</summary>
<content type="html">Nov. 4 (Bloomberg) -- Merck KGaA of Germany is gambling an unproven therapy that spurs the immune system to attack cancer cells will increase its share of a $48 billion oncology market. Merck is enrolling more than 900 women globally in an...</content>
<source>
<title>bloomberg.com</title>
</source>
<bx:external-link>http://www.bloomberg.com/apps/news?pid=20601085&amp;sid=aD2rO8iba81U</bx:external-link>
<bx:adder>
<bx:fullname>Rashmi Pant</bx:fullname>
<bx:id>rpant537</bx:id>
<bx:link href="http://bx.businessweek.com/profile/rashmi-pant/rpant537/"/>
</bx:adder>
<bx:action>
<bx:total>1</bx:total>
<bx:view>1</bx:view>
<bx:save>0</bx:save>
<bx:reaction>0</bx:reaction>
</bx:action>
</entry>
<entry>
<title>Personal Brain 5 Review</title>
<link href="/competitive-intelligence/personal-brain-5-review/368105247291617624-e2709a58169d3c17b1e2c84bd23122fb/"/>
<id>urn:com:businessweek:bx:article:368105247291617624-e2709a58169d3c17b1e2c84bd23122fb</id>
<updated>2009-04-01T23:57:00.000-04:00</updated>
<summary>4. Competitive Intelligence and Product Development. Okay I like this one too. I think it could be a great addition to any PersonalBrain though...</summary>
<content type="html">4. Competitive Intelligence and Product Development. Okay I like this one too. I think it could be a great addition to any PersonalBrain though...</content>
<source>
<title>Best Tool For the Job</title>
</source>
<bx:external-link>http://feedproxy.google.com/~r/BestToolForTheJob/~3/ZbF38Odm6xk/</bx:external-link>
<bx:adder>
<bx:fullname></bx:fullname>
<bx:id></bx:id>
<bx:link href=""/>
</bx:adder>
<bx:action>
<bx:total>58</bx:total>
<bx:view>58</bx:view>
<bx:save>0</bx:save>
<bx:reaction>0</bx:reaction>
</bx:action>
</entry>
<entry>
<title>Apple: Secrecy Does Not Scale</title>
<link href="/competitive-intelligence/apple-secrecy-does-not-scale/7293686699516770245-31f49b6608d758d5e9048ce7d7055e6c/"/>
<id>urn:com:businessweek:bx:article:7293686699516770245-31f49b6608d758d5e9048ce7d7055e6c</id>
<updated>2009-07-31T21:18:08.706-04:00</updated>
<summary>An extremely convincing case -- relentless point after point -- by Anil Dash against Apple for their obsession with secrecy at the expense of everything else around them. Everyone who is interested in Apple products must read this blog entry. Must read.</summary>
<content type="html">An extremely convincing case -- relentless point after point -- by Anil Dash against Apple for their obsession with secrecy at the expense of everything else around them. Everyone who is interested in Apple products must read this blog entry. Must read.</content>
<source>
<title>dashes.com</title>
</source>
<bx:external-link>http://dashes.com/anil/2009/07/apple-secrecy-does-not-scale.html</bx:external-link>
<bx:adder>
<bx:fullname>Thomas Huynh</bx:fullname>
<bx:id>thuynh381</bx:id>
<bx:link href="http://bx.businessweek.com/profile/thomas-huynh/thuynh381/"/>
</bx:adder>
<bx:action>
<bx:total>2</bx:total>
<bx:view>1</bx:view>
<bx:save>0</bx:save>
<bx:reaction>1</bx:reaction>
</bx:action>
</entry>
<entry>
<title>CEOs who sell gain clarity on competitive strategy</title>
<link href="/competitive-intelligence/ceos-who-sell-gain-clarity-on-competitive-strategy/846149244651606275-3c457e745630f75d7c89ef7e9a8eea5f/"/>
<id>urn:com:businessweek:bx:article:846149244651606275-3c457e745630f75d7c89ef7e9a8eea5f</id>
<updated>2009-04-24T16:13:01.250-04:00</updated>
<summary>Carol Hymnowitz’s recent Wall Street Journal article “CEOs Are Spending More Quality Time With Their Customers” highlights a trend that can directly impact your company’s competitive strategy. CEOs of Nike, Intel and Sun are becoming more involved...</summary>
<content type="html">Carol Hymnowitz’s recent Wall Street Journal article “CEOs Are Spending More Quality Time With Their Customers” highlights a trend that can directly impact your company’s competitive strategy. CEOs of Nike, Intel and Sun are becoming more involved...</content>
<source>
<title>marketingmo.com</title>
</source>
<bx:external-link>http://www.marketingmo.com/how-to-articles/competitive-positioning/ceos-who-sell-gain-clarity-on-competitive-strategy/</bx:external-link>
<bx:adder>
<bx:fullname>Michael Pizzo</bx:fullname>
<bx:id>mpizzo156</bx:id>
<bx:link href="http://bx.businessweek.com/profile/michael-pizzo/mpizzo156/"/>
</bx:adder>
<bx:action>
<bx:total>10</bx:total>
<bx:view>9</bx:view>
<bx:save>0</bx:save>
<bx:reaction>1</bx:reaction>
</bx:action>
</entry>
<entry>
<title>Global Competitive Intelligence Blueprint (Competitive Intelligence Magazine Article)</title>
<link href="/competitive-intelligence/global-competitive-intelligence-blueprint-competitive-intelligence-magazine-article/3946848562998567647-90409a8f64c13db2c9cbcfa646cd4a26/"/>
<id>urn:com:businessweek:bx:article:3946848562998567647-90409a8f64c13db2c9cbcfa646cd4a26</id>
<updated>2009-06-29T11:57:41.254-04:00</updated>
<summary>Global markets are a tempestuous sea of risks and opportunities for many companies. Competitive intelligence is not just a means of growth, but a requirement for survival no matter what the company’s size. Missteps and misunderstandings in global markets can cost billions of dollars. Companies are now creating positions dedicated to their strategic objectives, such as chief strategy officer, to better achieve their competitive objectives. </summary>
<content type="html">Global markets are a tempestuous sea of risks and opportunities for many companies. Competitive intelligence is not just a means of growth, but a requirement for survival no matter what the company’s size. Missteps and misunderstandings in global markets can cost billions of dollars. Companies are now creating positions dedicated to their strategic objectives, such as chief strategy officer, to better achieve their competitive objectives. </content>
<source>
<title>blog.sisinternational.com</title>
</source>
<bx:external-link>http://blog.sisinternational.com/ruth-stanat-journal/2008/5/29/global-competitive-intelligence-blueprint-by-ruth-stanat-com.html</bx:external-link>
<bx:adder>
<bx:fullname>Ruth Stanat</bx:fullname>
<bx:id>rstanat095</bx:id>
<bx:link href="http://bx.businessweek.com/profile/ruth-stanat/rstanat095/"/>
</bx:adder>
<bx:action>
<bx:total>3</bx:total>
<bx:view>3</bx:view>
<bx:save>0</bx:save>
<bx:reaction>0</bx:reaction>
</bx:action>
</entry>
<entry>
<title>Investorside panel on The Future of Expert Networks</title>
<link href="/competitive-intelligence/investorside-panel-on-the-future-of-expert-networks/8759862320052622622-8782105826e8ece00b2c9a84a5623bbb/"/>
<id>urn:com:businessweek:bx:article:8759862320052622622-8782105826e8ece00b2c9a84a5623bbb</id>
<updated>2009-04-13T23:03:00.000-04:00</updated>
<summary>Anne Maffei: Dmitri Mehlhorn might say CFO. We’d say biz dev, R&amp;D, product manager, competitive intelligence.</summary>
<content type="html">Anne Maffei: Dmitri Mehlhorn might say CFO. We’d say biz dev, R&amp;D, product manager, competitive intelligence.</content>
<source>
<title>Investment Banking, Research, and Operating Executives for Private Equity &amp; Vent</title>
</source>
<bx:external-link>http://feedproxy.google.com/~r/BrainFoodBlog/~3/LAj9uujH2v0/investorside-panel-on-the-future-of-expert-networks</bx:external-link>
<bx:adder>
<bx:fullname></bx:fullname>
<bx:id></bx:id>
<bx:link href=""/>
</bx:adder>
<bx:action>
<bx:total>5</bx:total>
<bx:view>5</bx:view>
<bx:save>0</bx:save>
<bx:reaction>0</bx:reaction>
</bx:action>
</entry>
<entry>
<title>Leading Email Marketing Intelligence Company Launches Competitive Email Intelligence Tool</title>
<link href="/competitive-intelligence/leading-email-marketing-intelligence-company-launches-competitive-email-intelligence-tool/3816273695866156159-e79fb765325369291c091aa5d50db722/"/>
<id>urn:com:businessweek:bx:article:3816273695866156159-e79fb765325369291c091aa5d50db722</id>
<updated>2009-01-29T03:51:00.000-05:00</updated>
<summary>NEW YORK--(Business Wire)-- Email Data Source, Inc. the email marketing industry&#39;s original source for email competitive intelligence has announced their newest product aptly called Alerts. The web-based module notifies a subscriber when any of the</summary>
<content type="html">NEW YORK--(Business Wire)-- Email Data Source, Inc. the email marketing industry&#39;s original source for email competitive intelligence has announced their newest product aptly called Alerts. The web-based module notifies a subscriber when any of the</content>
<source>
<title>Reuters</title>
</source>
<bx:external-link>http://c.moreover.com/click/here.pl?r1795183382&amp;f=9791</bx:external-link>
<bx:adder>
<bx:fullname></bx:fullname>
<bx:id></bx:id>
<bx:link href=""/>
</bx:adder>
<bx:action>
<bx:total>5</bx:total>
<bx:view>5</bx:view>
<bx:save>0</bx:save>
<bx:reaction>0</bx:reaction>
</bx:action>
</entry>
<entry>
<title>SharePoint as a competitive intelligence tool</title>
<link href="/competitive-intelligence/sharepoint-as-a-competitive-intelligence-tool/11821910587255257347-9eed5ec3639a7d36e4ad9d97cf830f7f/"/>
<id>urn:com:businessweek:bx:article:11821910587255257347-9eed5ec3639a7d36e4ad9d97cf830f7f</id>
<updated>2009-03-20T13:57:00.000-04:00</updated>
<summary>Pros &amp; cons of SharePoint as a competitive intelligence tool from the perspective of a CI software vendor.</summary>
<content type="html">Pros &amp; cons of SharePoint as a competitive intelligence tool from the perspective of a CI software vendor.</content>
<source>
<title>Montague Institute Review</title>
</source>
<bx:external-link>http://www.montague.com/review/cipher.html</bx:external-link>
<bx:adder>
<bx:fullname></bx:fullname>
<bx:id></bx:id>
<bx:link href=""/>
</bx:adder>
<bx:action>
<bx:total>6</bx:total>
<bx:view>6</bx:view>
<bx:save>0</bx:save>
<bx:reaction>0</bx:reaction>
</bx:action>
</entry>
<entry>
<title>Interview with Avinash Kaushik, Analytics Evangelist for Google</title>
<link href="/competitive-intelligence/interview-with-avinash-kaushik-analytics-evangelist-for-google/3848308069397728845-4ee938e0912576ae021ddcb7ba257f31/"/>
<id>urn:com:businessweek:bx:article:3848308069397728845-4ee938e0912576ae021ddcb7ba257f31</id>
<updated>2009-04-03T02:33:00.000-04:00</updated>
<summary>...be they web analytics (Google Analytics), web optimization (Google Website Optimizer), or competitive intelligence (Insights for Search...</summary>
<content type="html">...be they web analytics (Google Analytics), web optimization (Google Website Optimizer), or competitive intelligence (Insights for Search...</content>
<source>
<title>altex marketing - innovative internet marketing TM</title>
</source>
<bx:external-link>http://feedproxy.google.com/~r/altex/~3/IgzCMuR4jjc/interview-with-avinash-kaushik-analytics-evangelist-for-google</bx:external-link>
<bx:adder>
<bx:fullname></bx:fullname>
<bx:id></bx:id>
<bx:link href=""/>
</bx:adder>
<bx:action>
<bx:total>3</bx:total>
<bx:view>3</bx:view>
<bx:save>0</bx:save>
<bx:reaction>0</bx:reaction>
</bx:action>
</entry>
</feed>